SK Biopharmaceuticals CEO Lee Donghoon Purchases 180 Million Won Worth of Shares... "Demonstrating Responsible Management"

"Management's Commitment to Mid- to Long-Term Growth"

Donghoon Lee, CEO of SK Biopharmaceuticals, has purchased company shares worth 180 million won.

According to a disclosure by SK Biopharmaceuticals on the 31st, CEO Lee acquired 2,000 shares of common stock through an on-exchange transaction on the 27th. The average purchase price per share was 90,898 won.

Donghoon Lee, CEO of SK Biopharmaceuticals, is making a presentation at a press conference held at the Westin Chosun in Jung-gu, Seoul on the 26th. SK Biopharmaceuticals

This stock purchase took place the day after the press conference on the 26th, where the introduction of Opacalim was announced. SK Biopharmaceuticals plans to develop Opacalim as its next-generation global new drug candidate, following Cenobamate.

SK Biopharmaceuticals explained, "This reflects management's commitment to the company's mid- to long-term growth, based on the solid growth trajectory of Cenobamate and next-generation growth engines including Opacalim."

Yoo Changho, head of strategy at SK Biopharmaceuticals, who led the Opacalim acquisition deal, also participated in responsible management by purchasing 500 shares of company stock.

Opacalim is a selective potassium channel Kv7 activator, currently undergoing phase 2/3 clinical trials targeting adult patients with partial-onset seizures (POS). SK Biopharmaceuticals is targeting a U.S. market launch as early as 2029.

This content was produced with the assistance of AI translation services.